The constitutive androstane receptor protects against metabolic dysfunction-associated steatotic liver disease through sex specific interactions with the gut microbiota
Year: 2026
Type: preprint
Abstract: ABSTRACT Background The gut-liver axis is involved in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), but the host molecular actors involved in such dialogue have not yet been fully characterized. Objective We investigated the sex-dependent role of the Constitutive Androstane Receptor (CAR) as a hepatic sensor of microbial signals in MASLD pathophysiology. Design Male and female Car+/+ and Car-/- mice were fed a western diet (WD) for 4, 14 or 35 weeks. We performed plasma biochemistry, liver histology, bile acid and cholesterol quantification, untargeted multi-omics approach combining liver RNA-sequencing and 16S rRNA sequencing, together with co-housing, fecal microbiota transplantation and analysis of publicly available transcriptomics data in human cohorts. Results Short-term WD revealed CAR-dependent protection against steatosis, together with perturbations in the transcriptional signatures of multiple transcription factors involved in hepatocyte identity in males. After 14 weeks, CAR deletion increased WD-induced liver damage, inflammation and fibrosis, and disrupted bile acid, cholesterol and gut microbiota homeostasis, in males only. Co-housing and fecal microbiota transplantations revealed that a Car+/+ gut microbiota protected against WD-induced liver damage, while a Car-/- microbiota was reshaped by a Car+/+ host. No CAR-dependent phenotype was observed in females. Finally, in human cohorts, hepatic CAR expression decreased in advanced clinical stages of MASLD. Conclusion CAR is a sex-dependent protective nuclear receptor against MASLD progression, acting both as a transcriptional regulator of hepatocyte identity and as a mediator of the host-microbiota crosstalk. KEY MESSAGES What is already known on this topic The gut-liver axis contributes to Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) progression. CAR is a liver enriched nuclear receptor with sex-dependent activity, recognizing a broad range of xenobiotic and endobiotic metabolites and regulating xenobiotic, glucose, lipid, bile acid and cholesterol metabolism. New studies have also unveiled its ability to recognize bacterial-derived metabolites under physiological conditions. However, its role in MASLD remains controversial. The only FDA-approved drug for advanced MASLD targets a liver nuclear receptor (thyroid hormone receptor-β) but is effective in fewer than a third of patients. What this study adds CAR is required for the adaptive transcriptional response of hepatocytes to a western diet, acting as an upstream regulator of multiple transcription factors during early MASLD. CAR protects against MASLD in a sex-dependent manner through a causal, bidirectional crosstalk with the gut microbiota, as demonstrated by co-housing and fecal microbiota transplantation experiments In patient cohorts, hepatic CAR mRNA expression decreases at advanced MASLD clinical stages. How this study might affect research, practice or policy Nuclear receptor mechanisms in metabolic disease should be systematically assessed for sex dimorphism, as protective pathways identified in one sex may not generalise to the other. These findings suggest that both the gut microbiota and CAR itself could be targeted, in a sex-informed manner, as therapeutic strategies for MASLD. VISUAL ABSTRACT
Authors: Marine Huillet, Céline M.P. Martin, Guillaume Magne, Frédéric Lasserre, Justine Bruse, Valérie Alquier-Bacquié, Arnaud Polizzi, Clémence Rives, Prunelle Perrier, Noémie Poirier-Jaouen, Sarra Smati, Géraldine Garcia, Jelskey Gomes, Elodie Rousseau-Bacquié, Claire Naylies, Gaëlle Payros, Yannick Lippi, Théo Perion, Emilien L. Jamin, Rolle-Kampczyk Ulrike, Martin von Bergen, Justine Bertrand-Michel, Véronique Pons, Alexandra Montagner, Pierre Gourdy, JingHong Wan, Sophie Lotersztajn, Emmanuelle Vallez, Anne Muhr-Tailleux, Bart Staels, Charlène J.G. Dauriat, Benoit Chassaing, Michael Schupp, Yuna Blum, Anne Fougerat, Laurence Gamet-Payrastre, Bruno Lamas, Hervé Guillou, Nicolas Loiseau, Sandrine Ellero-Simatos
Institutions: École Nationale Vétérinaire de Toulouse, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Ecole d'Ingénieurs de PURPAN, Toxicologie Alimentaire, Université de Toulouse, Centre National de la Recherche Scientifique, Inserm, Institut du Thorax, Université de Nantes, Nantes Université, Helmholtz Centre for Environmental Research, Institut des Maladies Métaboliques et Cardiovasculaires, Centre de Recherche sur l'Inflammation, Université de Lille, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires, Institut Pasteur, Université Paris Cité, Microbiologie Intégrative et Moléculaire, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité – Universitätsmedizin Berlin, Institut de génétique et de développement de Rennes, Université de Rennes
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: EMULBIONT: Impact of dietary food additive EMULsifiers on pathoBIONT’s pathogenic potential in chronic inflammatory diseases: from mechanism to prevention, G3002025224, Dynamique de la REsistance aux Antibiotiques dans le Microbiote intestinal humain: combinaison d'une cohorte informée sur nutrition à des études quantitatives sur un modèle in vitro d'intestin, Harnessing molecular sex differences for personalized approaches in NAFLD management, Microbiota-Additives Interaction Mapping and Mechanisms for Personalized Nutrition in the Healthy and Diseased Populations, G5296751580, Glyphosate, diet and genetics: interactions via the gut microbiota and effects on host’s health, G7080048889, Institut des maladies inflammatoires chroniques intestinales de Nancy
OpenAlex ID: W7221441350
